☰

Kanak S. Raina, Ph.D. - Publications

Affiliations: 
Yale University, New Haven, CT 
Area:
organic synthesis, pharmacology, molecular biology
Tree Info Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Raina K, Forbes CD, Stronk R, Rappi JP, Eastman KJ, Gerritz SW, Yu X, Li H, Bhardwaj A, Forgione M, Hundt A, King MP, Posner ZM, Denny A, McGovern A, et al. Regulated Induced Proximity Targeting Chimeras (RIPTACs): a Novel Heterobifunctional Small Molecule Therapeutic Strategy for Killing Cancer Cells Selectively. Biorxiv : the Preprint Server For Biology. PMID 36711980 DOI: 10.1101/2023.01.01.522436  0.691
2019 Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, et al. RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. PMID 31023702 DOI: 10.1182/Blood.2018893982  0.621
2018 Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, et al. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. PMID 30575820 DOI: 10.1038/S41375-018-0334-3  0.571
2018 Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. PMID 29581547 DOI: 10.1038/S41375-018-0044-X  0.684
2018 Neklesa T, Snyder LB, Willard RR, Vitale N, Raina K, Pizzano J, Gordon D, Bookbinder M, Macaluso J, Dong H, Liu Z, Ferraro C, Wang G, Wang J, Crews CM, et al. Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer Cancer Research. 78: 5236-5236. DOI: 10.1158/1538-7445.Am2018-5236  0.567
2017 Crew AP, Raina K, Dong H, Qian Y, Wang J, Vigil D, Serebrenik YV, Hamman BD, Morgan A, Ferraro C, Siu K, Neklesa TK, Winkler JD, Coleman KG, Crews CM. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. Journal of Medicinal Chemistry. PMID 28692295 DOI: 10.1021/Acs.Jmedchem.7B00635  0.639
2017 Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. PMID 28663582 DOI: 10.1038/Leu.2017.207  0.686
2017 Raina K, Crews CM. Targeted protein knockdown using small molecule degraders. Current Opinion in Chemical Biology. 39: 46-53. PMID 28605671 DOI: 10.1016/J.Cbpa.2017.05.016  0.694
2017 Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, et al. Novel BET protein proteolysis targeting chimera (BET-PROTAC) exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Leukemia. PMID 28042144 DOI: 10.1038/Leu.2016.393  0.689
2017 Neklesa TK, Snyder LB, Bookbinder M, Chen X, Crew AP, Crews CM, Dong H, Gordon DA, Raina K, Rossi AK, Taylor I, Vitale N, Wang J, Willard RR, Zimmermann K. An oral androgen receptor PROTAC degrader for prostate cancer. Journal of Clinical Oncology. 35: 273-273. DOI: 10.1200/Jco.2017.35.6_Suppl.273  0.602
2017 Sun B, Fiskus W, Raina K, Qian Y, Crew A, Saenz DT, Mill CP, Nowak AJ, Saenz DN, Crews CM, Bhalla KN. Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells Blood. 130: 1265-1265. DOI: 10.1182/Blood.V130.Suppl_1.1265.1265  0.671
2017 Neklesa TK, Snyder LB, Bookbinder M, Chen X, Crew AP, Crews CM, Dong H, Gordon D, Macaluso J, Raina K, Rossi A, Taylor I, Vitale N, Wang J, Willard RR, et al. Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer Cancer Research. 77: 5637-5637. DOI: 10.1158/1538-7445.Am2017-5637  0.577
2017 Gough SM, Raina K, Gordon D, Willard R, Altieri M, Shen A, Qian Y, Neklesa T, Coleman K, Taylor I. Abstract 5076: IHC and flow cytometry quantifies BRD4 levels in surrogate tissues after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC Cancer Research. 77: 5076-5076. DOI: 10.1158/1538-7445.Am2017-5076  0.385
2017 Saenz DT, Fiskus WC, Raina K, Manshouri T, Coleman KG, Qian Y, Crew AP, Shen A, Mill CP, Sun B, Kim M, Nowak AJ, Verstovsek S, Crews CM, Bhalla KN. Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells Cancer Research. 77: 5067-5067. DOI: 10.1158/1538-7445.Am2017-5067  0.627
2016 Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K, Winkler JD, Crew AP, Crews CM, Coleman KG. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 27274052 DOI: 10.1073/Pnas.1521738113  0.602
2016 Saenz DT, Fiskus W, Raina K, Manshouri T, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Mill CP, Sun B, Verstovsek S, Crews C, Bhalla KN. Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells Blood. 128: 747-747. DOI: 10.1182/Blood.V128.22.747.747  0.622
2016 Sun B, Fiskus W, Zhang L, Raina K, Coleman K, Winkler J, Qian Y, Crew A, Shen A, Saenz DT, Mill CP, Wang M, Crews C, Bhalla KN. Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells Blood. 128: 1058-1058. DOI: 10.1182/Blood.V128.22.1058.1058  0.651
2016 Raina K, Lu J, Qian Y, Altieri M, Dong H, Wang J, Chen X, Crew A, Coleman K, Crews C, Winkler J. Abstract 4710: BRD4 degradation by PROTACs represents a more effective therapeutic strategy than BRD4 inhibitors in ovarian cancer Cancer Research. 76: 4710-4710. DOI: 10.1158/1538-7445.Am2016-4710  0.632
2016 Saenz DT, Fiskus WC, Manshouri T, Lu J, Qian Y, Raina K, Sun B, Krieger SS, Parmar S, Verstovsek S, Bhalla KN. Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells Cancer Research. 76: 4699-4699. DOI: 10.1158/1538-7445.Am2016-4699  0.518
2015 Buckley DL, Raina K, Darricarrere N, Hines J, Gustafson JL, Smith IE, Miah AH, Harling JD, Crews CM. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. Acs Chemical Biology. PMID 26070106 DOI: 10.1021/Acschembio.5B00442  0.769
2015 Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Hines J, Winkler JD, Crew AP, Coleman K, Crews CM. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chemistry & Biology. 22: 755-63. PMID 26051217 DOI: 10.1016/J.Chembiol.2015.05.009  0.67
2015 Coleman K, Lu J, Qian Y, Altieri M, Raina K, Dong H, Wang J, Hines J, Crew AP, Crews CM. BRD4 degraders produce long-lasting loss of BRD4 Ppotein and robust efficacy in Burkitt’s lymphoma cells. Journal of Clinical Oncology. 33: 8557-8557. DOI: 10.1200/Jco.2015.33.15_Suppl.8557  0.615
2015 Lu J, Qian Y, Raina K, Altieri M, Dong H, Wang J, Chen X, Crew A, Coleman K, Crews C, Winkler J. BRD4 Degradation By Protacs Represents a More Effective Therapeutic Strategy Than BRD4 Inhibitors in DLBCL Blood. 126: 2050-2050. DOI: 10.1182/Blood.V126.23.2050.2050  0.639
2015 Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, Winkler J, Crew A, Coleman K, Hines J, Crews C. Abstract LB-010: Hijacking the E3 ubiquitin ligase cereblon to create efficient BRD4 degraders Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-010  0.53
2014 Raina K, Noblin DJ, Serebrenik YV, Adams A, Zhao C, Crews CM. Targeted protein destabilization reveals an estrogen-mediated ER stress response. Nature Chemical Biology. 10: 957-62. PMID 25242550 DOI: 10.1038/Nchembio.1638  0.728
2012 Tae HS, Sundberg TB, Neklesa TK, Noblin DJ, Gustafson JL, Roth AG, Raina K, Crews CM. Identification of hydrophobic tags for the degradation of stabilized proteins. Chembiochem : a European Journal of Chemical Biology. 13: 538-41. PMID 22271667 DOI: 10.1002/Cbic.201100793  0.74
2011 Neklesa TK, Tae HS, Schneekloth AR, Stulberg MJ, Corson TW, Sundberg TB, Raina K, Holley SA, Crews CM. Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. Nature Chemical Biology. 7: 538-43. PMID 21725302 DOI: 10.1038/Nchembio.597  0.71
2010 Raina K, Crews CM. Chemical inducers of targeted protein degradation. The Journal of Biological Chemistry. 285: 11057-60. PMID 20147751 DOI: 10.1074/Jbc.R109.078105  0.677
Show low-probability matches.